The American Journal of Managed Care

FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis

The approval is the first in more than a decade for an idiopathic pulmonary fibrosis treatment. The FDA has approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of adults with ...
Medscape

Nerandomilast May Slow Down Progressive Pulmonary Fibrosis

In a phase 3 study, nerandomilast administered at 18 mg or 9 mg twice daily slowed the progression of pulmonary fibrosis in adults with progressive pulmonary fibrosis. In a previous study, ...

New analyses from FIBRONEER™ trials suggest survival benefit with nerandomilast in IPF and PPF

Not intended for UK and US audiences Nerandomilast long-term survival modeling presented at American Thoracic Society (ATS) 2026 and European ...
Medscape

Nerandomilast May Have Mortality Benefit for Patients With Autoimmune Lung Disease

GLASGOW, Scotland — The antifibrotic medication nerandomilast works in people with rheumatic disease and progressive pulmonary fibrosis (PPF) just as well as it does in the general population of ...
The American Journal of Managed Care

Anti-Fibrotic Nerandomilast Proves Tolerable Compared With Other IPF/PPF Drugs

Nerandomilast, a novel anti-fibrotic agent with improved tolerability and a dual antifibrotic/immunomodulatory mechanism, showed sustained efficacy in the FIBRONEER ...
Yahoo Finance

U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

Ingelheim, Germany/Ridgefield, Connecticut, U.S. Idiopathic pulmonary fibrosis (IPF) is a progressive disease, causing a continuous decline in lung function.1 Approval is based on results from two ...
Yahoo Finance

Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study

Boehringer Ingelheim image · GlobeNewswire Inc. Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from ...
Healio

Nerandomilast lowers FVC decline in progressive pulmonary fibrosis at 52 weeks

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Oral nerandomilast doses of 9 mg and 18 mg were ...
Medical Xpress

Pulmonary fibrosis: Nerandomilast inhibits phosphodiesterase 4B, may treat multiple forms of disease

A new drug for pulmonary fibrosis has reduced disease progression by more than 50% over a 52-week treatment in two clinical trials. Pulmonary fibrosis is a very serious disease, with a life prognosis ...
manilatimes

JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment

JASCAYD® (nerandomilast) now approved by Japan’s MHLW for the treatment of adults with idiopathic pulmonary fibrosis and adults with progressive pulmonary fibrosis Approval enables access to the first ...
Healio

Nerandomilast reduces FVC decline, has ‘manageable’ adverse events in IPF at 52 weeks

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Two differing nerandomilast doses were assessed against ...